Abstract:The anti‐inflammatory and neuroprotective mechanisms of the novel drug LIGc in models of neuroinflammation and cerebral ischemic injury involve its ability to downregulate the expression of the FPR1/NLRP3 signaling pathway in microglia/macrophages. This regulation facilitates the transformation of these cells into an anti‐inflammatory phenotype, leading to inhibition of pro‐inflammatory factor release and promotion of anti‐inflammatory factor production. Background Microglia/macrophages, as pivotal immune cells in the central nervous system (CNS), play a critical role in neuroinflammation associated with ischemic brain injury. Targeting their activation through pharmacological interventions represents a promising strategy to alleviate neurological deficits, thereby harboring significant implications for the prevention and treatment of ischemic stroke. Ligusticum cycloprolactam (LIGc), a novel monomeric derivative of traditional Chinese medicine, has shown potential as a therapeutic agent; however, its specific role in cerebral ischemic injury remains unclear. Methods In vitro experiments utilized lipopolysaccharide (LPS)‐induced inflammation models of RAW264.7 cells and primary mouse microglia. In vivo studies employed LPS‐induced neuroinflammation models in mice and a transient middle cerebral artery occlusion (tMCAO) mouse model to evaluate the impact of LIGc on neuroinflammation and microglia/macrophage phenotypic alterations. Further elucidation of the molecular mechanisms underlying these effects was achieved through RNA‐Seq analyses. Results LIGc exhibited the capacity to attenuate LPS‐induced production of pro‐inflammatory markers in macrophages and microglia, facilitating their transition to an anti‐inflammatory phenotype. In models of LPS‐induced neuroinflammation and tMCAO, LIGc ameliorated pathological behaviors and neurological deficits while mitigating brain inflammation. RNA‐seq analyses revealed formyl peptide receptor 1 (FPR1) as a critical mediator of LIGc's effects. Specifically, FPR1 enhances the pro‐inflammatory phenotype of microglia/macrophages and inhibits their anti‐inflammatory response by upregulating NLR family pyrin domain protein 3 (NLRP3) inflammasomes, thus aggravating inflammatory processes. Conversely, LIGc exerts anti‐inflammatory effects by downregulating the FPR1/NLRP3 signaling axis. Furthermore, FPR1 overexpression or NLRP3 agonists reversed the effects of LIGc observed in this study. Conclusion Our findings suggest that LIGc holds promise in improving ischemic brain injury and neuroinflammation through modulation of microglia/macrophage polarization. Mechanistically, LIGc attenuates the pro‐inflammatory phenotype and promotes the anti‐inflammatory phenotype by targeting the FPR1/NLRP3 signaling pathway, ultimately reducing inflammatory responses and mitigating neurological damage.

Z-ligustilide Attenuates Lipopolysaccharide-Induced Proinflammatory Response Via Inhibiting NF-κB Pathway in Primary Rat Microglia

Z-Ligustilide Inhibits LPS-induced Neuroimflammation via PPARγ-dependent Suppression of TLR4/NF-κB Signaling Pathway

Protective Effect of Z-ligustilide Against Amyloid Β-Induced Neurotoxicity is Associated with Decreased Pro-Inflammatory Markers in Rat Brains

A Novel Compound Ligusticum Cycloprolactam Alleviates Neuroinflammation After Ischemic Stroke via the FPR1/NLRP3 Signaling Axis

Z-ligustilide Protects BV-2 Microglial Cells Against Oxygen-Glucose Deprivation/reoxygenation-Induced Injury by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis

Ligustilide Ameliorates Neuroinflammation and Brain Injury in Focal Cerebral Ischemia/reperfusion Rats: Involvement of Inhibition of TLR4/peroxiredoxin 6 Signaling.

Luteolin Inhibits Microglial Inflammation and Improves Neuron Survival Against Inflammation

Interferon Regulatory Factor 5 Mediates Lipopolysaccharide-Induced Neuroinflammation

Mechanism of ligusticum cycloprolactam against neuroinflammation based on network pharmacology and experimental verification

Ligustrazine Ameliorates Lipopolysaccharide-Induced Neurocognitive Impairment By Activating Autophagy Via The Pi3k/Akt/Mtor Pathway

Gualou Guizhi Granule Suppresses LPS-Induced Inflammatory Response of Microglia and Protects Against Microglia-Mediated Neurotoxicity in HT-22 Via Akt/NF-κB Signaling Pathways

Inhibitory Effect of Ginsenoside Rg1 on Lipopolysaccharide-Induced Microglial Activation in Mice

Anti-Neuroinflammatory Effects of a Semi-Synthetic Isoorientin-Based Glycogen Synthase Kinase-3β Inhibitor in Lipopolysaccharide-Activated Microglial Cells

Postischemic Administration of Z-Ligustilide Ameliorates Cognitive Dysfunction and Brain Damage Induced by Permanent Forebrain Ischemia in Rats

A Novel Quinolyl-Substituted Analogue of Resveratrol Inhibits LPS-Induced Inflammatory Responses in Microglial Cells by Blocking the NF-κB/MAPK Signaling Pathways

The role of ZC3H12D-regulated TLR4-NF-κB pathway in LPS-induced pro-inflammatory microglial activation

Protection Against Β-Amyloid-induced Neurotoxicity by Naturally Occurring Z-ligustilide Through the Concurrent Regulation of P38 and PI3-K/Akt Pathways.

Ligustilide Prevents LPS-induced Inos Expression in RAW 264.7 Macrophages by Preventing ROS Production and Down-Regulating the MAPK, NF-κB and AP-1 Signaling Pathways.

Neuroprotective Effect of Z-Ligustilide Against Permanent Focal Ischemic Damage in Rats

Neuroprotective role of Z-ligustilide against forebrain ischemic injury in ICR mice

Ligustilide attenuates nitric oxide-induced apoptosis in rat chondrocytes and cartilage degradation via inhibiting JNK and p38 MAPK pathways.